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GLOBOCAN 2018 has evaluated the cancer 
incidence rate among inhabitants of 185 nations 
around the globe. Cervical cancer keeps on being 
a general health issue influencing the middle-aged 
women, especially in less-resourced nations and is 
positioned as the fourth most common cancer in 
women, after breast (2·1 million cases), colorectal 
(0·8 million) and lung cancer (0·7 million) [1]. Cer-
vical cancer is the main source of disease-related 
death in women worldwide. India alongside China 
contributed in the excess of 33% of the worldwide 
cervical burden, with 106,000 cases in China and 
AbstrAct
background: acuros XB (aXB) may predict better rectal toxicities and treatment outcomes in cervix carcinoma. The aim of the 
study was to quantify the potential impact of aXB computations on the cervix radiotherapy using the rapidarc (ra) technique 
as compared to anisotropic analytical algorithm (aaa) computations.
Materials and methods: a cohort of 30 patients previously cared for cervix carcinoma (stages II–IIIB) was selected for the 
present analysis. The ra plans were computed using aaa and aXB dose computation engines under identical beam setup 
and MLc pattern.
results: There was no significant (p > 0.05) difference in D95% and D98% to the planning target volume (pTV); moreover, a 
significant (p < 0.05) rise was noticed for mean dose to the pTV (0.26%), D50% (0.26%), D2% (0.80%) and V110% (44.24%) for aXB 
computation as compared to aaa computations. Further, aXB estimated a significantly (p < 0.05) lower value for maximum 
and minimum dose to the pTV. additionally, there was a significant (p < 0.05) reduction observed in mean dose to organs at 
risk (Oars) for aXB computation as compared to aaa, though the reduction in mean dose was non-significant (p > 0.05) for 
the rectum. The maximum difference observed was 4.78% for the rectum V50Gy, 1.72%, 1.15% in mean dose and 2.22%, 1.48% 
in D2% of the left femur and right femur, respectively, between aaa and aXB dose estimations.
conclusion: For similar target coverage, there were significant differences observed between the aaa and aXB computations. 
aaa underestimates the V50Gy of the rectum and overestimates the mean dose and D2% for femoral heads as compared to aXB. 
Therefore, the use of aXB in the case of cervix carcinoma may predict better rectal toxicities and treatment outcomes in cervix 
carcinoma using the ra technique. 
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97,000 cases in India, and 48,000 deaths in China 
and 60,000 deaths in India [2].
Radiotherapy (RT) is generally utilized in the 
management of cervix carcinoma. Because the cer-
vix is surrounded with a heterogeneous medium 
such as bone and air pockets, the accuracy of a dose 
computation engine assumes an important role in 
order to achieve the maximum therapeutic benefits 
from the radiation treatment. Dose computation 
in RT, utilizes a radiation beam model to compute 
the beam fluence impinging on the patient body, 
subsequently, dose engine computes the particle 
transport and energy deposition in the body. En-
ergy deposition hinges on the heterogeneities that 
exist in the patient body and their influence on the 
primary and secondary particle fluence.
For photon, there are two dose computation 
engines employed in the Eclipse (Varian Medical 
System, USA) treatment planning system (TPS) 
viz., the anisotropic analytical algorithm (AAA) 
and the Acuros XB (AXB) algorithm. The AXB de-
ploys the same multiple-source model previously 
derived for AAA. However, AXB and AAA dose 
engines are mainly separated into: source model, 
configuration part, dose deposition engines for 
AAA and AXB. The AXB primarily processes the 
dose distribution based on the explicit solutions of 
the linear Boltzmann transport equation (LBTE) 
[3, 4]. The LBTE is a set of integro-differential 
equations that depict the interaction and transport 
of various particles (electrons, photons and neu-
trons, etc) in matter at the macroscopic level. The 
AXB patient dose computation consists of discrete 
steps viz., transport of source model fluence, flu-
ence calculation for scattered photon, electron and 
final dose calculation in the patient. The AXB re-
quires the macroscopic cross-section of the every 
element within the computation grid. The Eclipse 
TPS offers AXB material type and mass-density in 
each voxel of the image grid using a lookup table 
for 5 biological (adipose tissue, lung, muscle, car-
tilage and bone) and 16 non-biological materials, 
with a maximum supported Hounsfield units of 
8000 (steel) [5–7].
The AXB has been reported to be precise and 
equivalent to Monte-Carlo (MC) in dealing with 
heterogeneities encountered in clinical settings [8, 
9]. In cervix RT, there is a chance of alteration in 
the precision of dose computation engine due to the 
heterogeneities that exist around the tumor target 
volume. Therefore, it is important to evaluate the 
dosimetric difference in dose distribution comput-
ed using AAA and AXB for cervix carcinoma. The 
literature on the dosimetric comparison of AAA 
and AXB algorithms for carcinoma cervix RT is at 
a premium. The RapidArc (RA) technique has been 
reported superior for cervix RT as compared to 
the intensity modulated radiation therapy (IMRT) 
technique [10–12]. Hence, the present study is 
aimed to quantify the potential benefits of AXB 
computations on the cervix RT using RA technique 
as compared to AAA computations. The present 
study analyzes the dosimetric parameters in terms 
of target coverage, organ-at-risk (OARs) sparing 
and various physical dosimetric indices.
Materials and methods
A cohort of 30 patients previously cared for 
cervix carcinoma (stages II–IIIB) was selected for 
the present analysis. The computed-tomography 
(CT)-scan of 3 mm slice thickness was acquired on 
Siemens SOMATOM Sensation Open CT-scanner 
(Siemens Medical Solutions, Erlangen, Germa-
ny) for each patient. Patients were immobilized 
in a supine position using an All-In-One (AIO) 
board with full bladder according to the depart-
mental protocol. 
The target volume delineation was executed on 
the CT-images in accordance with Radiation Ther-
apy Oncology Group (RTOG) recommendations 
[13]. The clinical target volume (CTV) incorpo-
rated the uterus, cervix, pelvic nodes comprising 
parametrial and presacral tissues. An edge of 5.0 
mm was employed around the CTV to characterize 
the planning target volume (PTV) [14]. The ac-
companying OARs, i.e.: bladder, rectum, bowel and 
femoral heads, were additionally delineated.
The treatment plans were optimized for the RA 
technique using a double arc (clockwise: gantry an-
gle 179–181 degree and counter clockwise: gantry 
angle 181–179 degree, collimator rotation: 10–30 
degree). The plans were intended to deliver a pre-
scription dose (PD) of 50.4 Gray (Gy) to PTV in 28 
sittings at the rate of 1.8 Gy per part. The plans were 
optimized to deliver 100% PD to 95% of PTV with 
not more than 5% of PTV volume obtaining 110% 
of PD. The dose to the bladder and rectum was op-
timized in such a way that V50Gy (volume receiving 
50 Gy) ought to be under 50% of OAR volume.
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RA plans were created using Eclipse TPS for 6 
mega-volt (MV) photon beam (Varian Medical 
System, Palo, Alto, USA) generated from True-
Beam-STx (Varian Medical System, Palo, Alto, 
USA) linear accelerator (linac). Each treatment plan 
was computed using a grid resolution of 2.5 mm for 
AAA and AXB version 11 under identical beam 
geometry and MLC setup. For AXB computation, 
a physical material table was set to AXB version 11; 
for mapping of physical material using CT-Houn-
sfield units. The dose-to-medium (Dm) was used for 
dose reporting for AXB computation. 
Dosimetric analysis
The cumulative dose-volume histograms (DVH) 
were generated to evaluate and compare the various 
dosimetric parameters for the PTV and OARs. The 
following dose metrics were calculated for PTV 
and OARs.
• PTV: mean dose, D95% (dose to the 95% volume), 
D98%, D50%, D2%, V110% (volume receiving 110% of 
the PD), maximum and minimum doses to the 
PTV;
• bladder: mean, V50Gy (percentage of volume re-
ceiving dose of 50 Gy), maximum dose and D2%;
• rectum: mean, V50Gy, maximum dose and D2%;
• bowel: mean, maximum dose and D2%; 
• femoral heads: mean, maximum dose and D2%.
The dose conformity index (CI), homogeneity 
index (HI), gradient measure (GM) and integral 
dose to normal tissues (NTID) was calculated using 
the following formulae: 
• conformity index (CI): 
CI = Volume of 95% isodose/Volume of PTV [15];
• homogeneity index (HI): 
�HI� = �D�� − D����D���  
 
 [16].
The value of CI close to 1 and HI close to 0 sig-
nifies a better conformal and homogenous dose 
distribution to the PTV:
• gradient measure (GM): GM was determined 
as radius difference between the equivalent 
spheres of prescription and half prescription 
isodose volumes, which demonstrates dose 
falloff around PTV. The lower value for GM 
confirms a higher gradient in dose distribution 
around the target [16];
• integral dose to normal tissues (NTID): mean 
dose × normal tissues volume outside PTV [17].
The computation efficiency of dose engine was 
also examined by evaluating the Monitor units 
(MUs) and calculating time required for an indi-
vidual dose computation engine.
statistical analysis
The Estimation Statistics (ES) avoids the pitfalls 
of significance testing, and highlights the magni-
tude of the effect (the effect size) and its accura-
cy. ES provides a profound comprehension of the 
metrics used, and how they relate to the natural 
processes being considered. On the other hand, sig-
nificance testing computes the probability (p-value) 
that the experimental data would be observed, if 
the intervention did not generate an alteration in 
the metric estimated (i.e. the null hypothesis). This 
leads to a false dichotomy on the experimental in-
tervention [18]. The main advantage of ES is to re-
port an effect size along with its confidence interval 
(CI). The CI helps to evaluate the clinical as well as 
statistical significance of the difference [19]. There-
fore, ES was utilized to determine the variations in 
dosimetric indices for the present study. The metric 
of interest was demonstrated for every patient by 
means of swarm plots, with every patient’s informa-
tion for both algorithms shown via a line joining 
the two algorithms. The distribution on the right of 
every graph illustrates the CI of the variation in the 
means, with the zero location of this axis aligned 
with the mean of the control dose computation 
engine. The statistical analysis was executed us-
ing Python software version 3.8.3 (Python Software 
Foundation, Beaverton, USA).
results
RapidArc treatment plans were generated for 
both dose computation engines using the 6 MV 
photon beam. A comprehensive analysis was per-
formed for PTV and OARs in order to analyze the 
dosimetric variations between both dose computa-
tion engines. The dosimetric parameters for PTV 
coverage were detailed in Table 1. For a representa-
tive patient, Figure 1 illustrates the 95% PD cover-
age for cervix carcinoma using (a) AAA and (b) 
AXB dose computation. There was no significant 
(p > 0.05) difference in D95% and D98% to the PTV; 
moreover, a significant (p < 0.05) rise was noticed 
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for mean dose to PTV (0.26%), D50% (0.26%), D2% 
(0.80%) and V110% (44.24%) for AXB computation 
as compared to AAA computations. Further, AXB 
estimated a significantly (p < 0.05) lower value for 
maximum and minimum dose to the PTV. Figure 2 
illustrates the comparison between AAA and AXB 
estimated (a) D95%, (b) D50% and (c) V110% of the PTV.
Additionally, AXB estimated dose distribution 
was slightly inferior in terms of CI (p < 0.05, 0.60%), 
HI (p < 0.05, 7.41%), and superior in terms of GM 
(p < 0.05, 0.75%) compared to AAA. However, AXB 
estimated lower NTID (p < 0.05, 0.51%) as com-
pared to AAA computation. Figure 3 illustrates the 
comparison between AAA and AXB estimated (a) 
CI, (b) HI and (c) calculation time.
The dosimetric parameters for OARs computed 
using AAA and AXB dose engines were detailed 
in Table 2. There was a reduction in mean dose to 
the bladder (p < 0.05, 0.22%), rectum (p > 0.05, 
0.02%), bowel (p < 0.05, 0.45%) for AXB as com-
pared to AAA. On the other hand, a significant rise 
(p < 0.05) in maximum dose and D2%, was observed 
for the bladder (0.32% and 0.09%), rectum (0.56% 
and 0.49%) and bowel (0.93% and 0.29%), for AXB 
as compared to AAA. Similarly, a significant rise 
(p < 0.05) was observed in percentage volume of 
V50Gy for the bladder (0.93%) and rectum (4.78%), 
for AXB as compared to AAA.
Moreover, there was a significant (p < 0.05) re-
duction noticed for maximum dose (approx 0.50%) 
table 1. Dose-volume parameters for planning target volume (pTV) and dosimetric indices calculated for dose distribution 




(Mean ± SD) (Mean ± SD)
pTV
Mean [Gy] 52.73 ± 0.52 52.87 ± 0.53 0.000
D95% [Gy] 50.40 ± 0.02 50.40 ± 0.01 0.148
D98% [Gy] 49.59 ± 0.17 49.56 ± 0.22 0.100
D50% [Gy] 52.87 ± 0.57 53.01 ± 0.58 0.000
D2% [Gy] 54.88 ± 0.91 55.32 ± 0.90 0.000
V110 [%] 1.84 ± 2.60 3.30 ± 3.68 0.000
MaX [Gy] 57.29 ± 1.36 52.26 ± 0.23 0.000
MIN [Gy] 43.93 ± 2.05 43.04 ± 2.13 0.011
hI 0.100 ± 0.018 0.108 ± 0.019 0.000
cI 1.000 ± 0.015 1.006 ± 0.016 0.006
GM 3.903 ± 0.315 3.874 ± 0.319 0.000
NTID (liter-Gy) 11.78 ± 2.58 11.72 ± 2.56 0.000
sD — standard deviation; pTV — planned target volume; cI — conformity index; hI — homogeneity index; GM — gradient measure; NTID — integral dose  
to normal tissues
a B
Figure 1. example patient illustrating the 95% prescription dose coverage for cervix carcinoma using (A) aaa 
and (b) aXB dose computation
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and D2% (left femur: 1.15%, right femur: 1.48%) for 
both femoral heads for AXB as compared to AAA. 
Additionally, there was a significant (p < 0.05) re-
duction in mean dose to the left femur (1.72%) 
and right femur (2.22%) for AXB computations as 
compared to AAA.
Further, there was a significant increase in the 
number of calculated MUs (p < 0.05, 0.64%) with 
AXB algorithm but calculation time was 5.83% fast-
er, though statistically non-significant (p > 0.05) as 
shown in Table 3, as compared to AAA. Figure 4 
summarizes the absolute mean difference between 
AXB and AAA for cervix carcinoma.
Discussion
The study presents a comprehensive analysis of 
dose distribution generated for cervix carcinoma 
using AAA and AXB computation. The present 
study tried to quantify the impact of AXB compu-
tations on cervix carcinoma as compared to AAA 
computation. The study reveals that there was no 
significant (p > 0.05) difference in PTV coverage 
for both dose engines. However, there was a signifi-
cant (p < 0.05) difference in maximum and mini-
mum dose values to the PTV between both dose 
computations. Additionally, there was a reduction 
observed (p < 0.05) in mean dose to OARs for 
AXB computation as compared to AAA, although 
the reduction in mean dose was non-significant 
(p > 0.05) for the rectum.
Rana et al. [20] detailed the dosimetric differ-
ence between AAA and AXB for prostate cancer 
and concluded the highest dose difference was 
up to 0.43% and 1.98% for PTV and OARs be-
tween AAA and AXB computations using a partial 
Figure 3. comparison of conformity index (cI) (A), homogeneity index (hI) (b) and  calculation time (in sec) (c) between 
analytical algorithm (aaa) and acuros XB (aXB)
a B c
Figure 2. comparison of dose to the (A) D95%, (b) D50% and (c) percentage volume V110% for planning target volume (pTV)
a B c
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single arc VMAT plan. Further, Rana et al. [20] 
reported that AAA estimated higher maximum 
and minimum doses to PTV and higher mean 
dose to OARs as compared to AXB estimations. 
Our results were in congruence with the above-
mentioned study. 
Additionally, Koo et al. [21] detailed the dosi-
metric difference between AAA and AXB for pros-
tate cancer using endorectal balloon and concluded 
a higher value for V107% (hot-spot), and no signifi-
cant (p > 0.05) difference in CI and HI for AXB as 
compared to AAA estimation. The present study 
reveals a significantly higher V110% value for AXB 
estimation as compared to AAA. The study also 
reveals a significant difference in CI (0.60%), HI 
(7.41%), GM (0.75%) and NTID (0.51%) for AXB 
as compared to AAA estimations.
For OARs, the maximum difference was ob-
served for the volume of 50Gy (i.e. V50Gy) of the 
rectum (4.78%), mean dose (Lt femur 1.72% and 
Rt femur 2.22%) and D2% (Lt femur 1.15% and Rt 
femur 1.48%) to the femoral heads between AAA 
and AXB dose estimations. AAA underestimates 
the V50Gy of the rectum and overestimates the mean 
dose and D2% for the femoral heads as compared to 
AXB. This larger variation in V50Gy to the rectum 
can be attributed to the possible presence of air 
or gas-pockets in some part of the rectum. In ad-
dition, there was a difference in the computation 
approach used by both dose computation engines 
in modeling the scatter radiation and secondary 
electrons, when density is different from that of wa-
ter (i.e., air pockets and bony structure of femoral 
heads). The high-dose volume of the rectum may 





(Mean ± SD) (Mean ± SD)
Bladder
Mean [Gy] 41.45 ± 1.67 41.36 ± 1.67 0.000
V50Gy (%) 33.07 ± 4.82 33.38 ± 4.72 0.003
Max [Gy] 55.90 ± 1.28 56.08 ± 1.33 0.030
D2% [Gy] 53.95 ± 0.85 54.00 ± 0.87 0.056
rectum
Mean [Gy] 42.93 ± 2.70 42.92 ± 2.73 0.681
V50Gy (%) 25.70 ± 8.04 26.99 ± 8.43 0.000
Max [Gy] 54.92 ± 1.09 55.23 ± 1.20 0.000
D2% [Gy] 52.90 ± 0.70 53.16 ± 0.74 0.000
Bowel
Mean [Gy] 18.01 ± 3.17 17.93 ± 3.18 0.000
Max [Gy] 51.39 ± 3.54 51.87 ± 3.82 0.000
D2 [Gy] 41.13 ± 3.99 41.25 ± 4.03 0.000
Lt Femur
Mean [Gy] 20.65 ± 1.83 20.30 ± 1.81 0.000
Max [Gy] 50.84 ± 2.69 50.58 ± 2.76 0.003
D2% [Gy] 45.62 ± 3.84 45.10 ± 3.89 0.000
rt Femur
Mean [Gy] 20.72 ± 2.18 20.27 ± 2.06 0.000
Max [Gy] 51.56 ± 2.84 51.31 ± 2.95 0.007
D2% [Gy] 46.52 ± 4.04 45.84 ± 4.12 0.001
sD — standard deviation




(Mean ± SD) (Mean ± sD)
MUs 525.56 ± 32.74 528.93 ± 33.59 0.000
calculation time (s) 519.10 ± 58.49 490.50 ± 99.71 0.164
sD — standard deviation; Mus — monitor units; s — seconds
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lead to a high risk of rectal toxicity; similarly, the 
reduction in doses for femoral heads reduces the 
toxicity level for bony femoral heads. These differ-
ences in V50Gy of the rectum, mean that dose and 
D2% to the femoral heads may impact the treatment 
outcome and, therefore, cannot be simply ignored. 
Koo et al. [21] demonstrated the accuracy of AXB 
in air pockets and air-tissue interface as compared 
to AAA and concluded that AXB is more precise 
in forecasting the dose in air pockets and air-tissue 
interface based on the prostate cancer study using 
an endorectal balloon. The AXB has been reported 
to be more precise and comparable to MC in differ-
ent clinical studies [22, 23].  
Additionally, the present study also reveals a rise 
in MUs (p < 0.05, 0.64 %) and decrease in calcula-
tion time (p > 0.05, 5.83 %) required for the AXB 
computation as compared to AAA for similar target 
coverage in the case of cervix carcinoma. Faster 
dose computation is in the interest of contemporary 
RT clinics. 
To the best of our knowledge, this study is the 
first of its kind in comparing the dosimetric impact 
of AXB and AAA on external beam RT planning 
in carcinoma cervix. Owing to the lack of parallel 
literature on dosimetric impact of AXB on cervix 
carcinoma, dosimetric study executed on the pros-
tate was used for comparative analysis against the 
present study. 
Major drawback of the present study lies on its 
dependence on the dosimetric data rather than 
clinical evidence. However, the present study care-
fully investigates the potential dosimetric difference 
in AAA and AXB computation for cervix carci-
noma and presents a possible edge of using AXB 
over AAA estimations for cervix carcinoma using 
the RA technique.
conclusion
The present study demonstrates that, for a simi-
lar target coverage, there were significant differ-
ences observed between the AAA and AXB com-
putations for cervix carcinoma using the RA tech-
nique. The study reveals that AAA underestimates 
the V50Gy of the rectum and overestimates the mean 
dose and D2% for the femoral heads as compared to 
AXB. AXB performs a relativity faster computation 
as compared to AAA. Therefore, the use of AXB 
in cervix carcinoma may predict better rectal tox-
icities and treatment outcomes in cervix carcinoma 





Figure 4. summary of dosimetric comparison of various parameters for planning target volume (pTV) and organ at risks 
(Oars) for analytical algorithm (aaa) and acuros XB (aXB) dose computations
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